These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 9723270

  • 1. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine.
    Jirasiritham S, Sumethkul V, Mavichak V, Jirasiritham S.
    Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270
    [No Abstract] [Full Text] [Related]

  • 2. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
    Park K, Kim MS, Kim SI, Kim YS, Moon JI.
    Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
    [No Abstract] [Full Text] [Related]

  • 3. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
    Cossu M, Satta R, Branca GF, Pala PG, Serra G, Satta RP, Sorba G.
    Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
    [No Abstract] [Full Text] [Related]

  • 4. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C, Melchor JL.
    Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
    [No Abstract] [Full Text] [Related]

  • 5. Optimization of cyclosporine therapy in renal transplantation.
    Ponticelli C.
    Transplant Proc; 1998 Aug; 30(5):1718-20. PubMed ID: 9723254
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 8. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
    Foradori A, Pinto VM, Elberg A.
    Transplant Proc; 1998 Aug 27; 30(5):1666-7. PubMed ID: 9723235
    [No Abstract] [Full Text] [Related]

  • 9. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H, Asmundsson P, Clausen P, Dieperink H, Hansen JM, Heaf J, Jensen SB, Kornerup HJ, Madsen S, Pedersen EB, Poulsen JV, Rasmussen K.
    Transplant Proc; 1996 Aug 27; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract] [Full Text] [Related]

  • 10. Cyclosporine from twice to single daily dosing: impact on renal function, mortality, and graft loss.
    Bianco PD, Silva HT, Boni R, Machado PG, Pacheco-Silva A, Pestana JO.
    Transplant Proc; 2002 Nov 27; 34(7):2920-1. PubMed ID: 12431657
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
    Neumayer HH, Färber L, Budde K, Kohnen R, Maibücher A, Schuster A, Vollmar J, Waiser J, Luft FC.
    Transplant Proc; 1996 Aug 27; 28(4):2207-13. PubMed ID: 8769202
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH, Pang ST, Chiang YJ, Chuang CK, Chen HW, Chen CS, Chou CC, Huang CC.
    Transplant Proc; 1998 Nov 27; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract] [Full Text] [Related]

  • 15. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G, Korn A.
    Transplant Proc; 1996 Aug 27; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract] [Full Text] [Related]

  • 16. Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships.
    Mueller EA, Niese D, Mellein B.
    Transplant Proc; 1998 Aug 27; 30(5):1694-6. PubMed ID: 9723247
    [No Abstract] [Full Text] [Related]

  • 17. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB, Martin JE, Schroeder TJ, First MR.
    Transplant Proc; 1998 Dec 27; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
    Heroux AL, LeBlanc MH, Beaudoin D, Simard S, Coulombe DA, Gleeton O, Lemieux MD, Doyle DP.
    Transplant Proc; 1996 Dec 27; 28(6):3145-8. PubMed ID: 8962219
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.